[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100348403":3},{"organization":4,"armGroups":7,"interventions":60,"overallOfficials":136,"centralContacts":76,"locations":141,"responsibleParty":786,"collaborators":76,"id":788,"slug":789,"hasResults":790,"nctId":791,"briefTitle":792,"officialTitle":793,"acronym":76,"eligibilityCriteria":794,"healthyVolunteers":790,"sex":795,"minAge":796,"maxAge":76,"enrollmentInfo":797,"targetDuration":76,"studyType":800,"phases":801,"briefSummary":803,"conditions":804,"keywords":76,"overallStatus":168,"whyStopped":76,"lastUpdateSubmitDate":819,"lastUpdatePostDateStruct":820,"startDateStruct":823,"completionDateStruct":825,"leadSponsor":827,"locationsCount":828},{"fullName":5,"class":6},"National Cancer Institute (NCI)","NIH",[8,15,20,25,29,33,37,41,46,50,56],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (nivolumab)","EXPERIMENTAL","Patients may receive single agent nivolumab IV over 30 minutes every 4 weeks for up to 2 years for patients with metastatic indications, for up to 1 year for adjuvant indications or for up to 3 months after surgery for neoadjuvant indications in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,14],"Procedure: Biospecimen Collection","Biological: Nivolumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm II (nivolumab, ipilimumab)","Patients with unresectable or metastatic melanoma receive nivolumab IV over 30 minutes every 2 or 4 weeks in combination with ipilimumab IV every 3 weeks for up to 4 doses of combination therapy in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab may continue every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14],"Biological: Ipilimumab",{"label":21,"type":10,"description":22,"interventionNames":23},"Arm III (nivolumab, platinum doublet)","Patients receiving neoadjuvant treatment of resectable NSCLC receive nivolumab IV over 30 minutes in combination with platinum doublet therapy every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,14,24],"Drug: Platinum Doublet",{"label":26,"type":10,"description":27,"interventionNames":28},"Arm IV (nivolumab, ipilimumab)","Patients with metastatic PD-L1 positive NSCLC receive nivolumab IV over 30 minutes every 3 weeks and ipilimumab IV every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14],{"label":30,"type":10,"description":31,"interventionNames":32},"Arm IX (nivolumab, ipilimumab)","Patients with HCC receive nivolumab IV over 30 minutes in combination with ipilimumab IV every 3 weeks for up to 4 doses of combination therapy. Patients may continue to receive single agent nivolumab every 2 or 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14],{"label":34,"type":10,"description":35,"interventionNames":36},"Arm V (nivolumab, ipilimumab, platinum doublet therapy)","Patients with metastatic or recurrent NSCLC receive nivolumab IV over 30 minutes every 3 weeks, ipilimumab IV every 6 weeks and platinum doublet therapy every 3 weeks for up to 2 cycles of combination therapy. Treatment with nivolumab and ipilimumab repeats for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14,24],{"label":38,"type":10,"description":39,"interventionNames":40},"Arm VI (nivolumab, ipilimumab)","Patients with malignant pleural mesothelioma receive nivolumab IV over 30 minutes every 3 weeks and ipilimumab IV every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14],{"label":42,"type":10,"description":43,"interventionNames":44},"Arm VII (nivolumab, ipilimumab, cabozantinib)","Patients with advanced RCC receive nivolumab IV over 30 minutes in combination with ipilimumab IV every 3 weeks for up to 4 doses of combination therapy in the absence of disease progression or unacceptable toxicity. Patients may continue to receive single agent nivolumab every 2 or 4 weeks in the absence of disease progression or unacceptable toxicity. Patients may optionally receive nivolumab IV every 2 or 4 weeks in combination with cabozantinib PO QD for up to 2 years of combination therapy in the absence of disease progression or unacceptable toxicity. Treatment with single agent cabozantinib may continue in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,45,19,14],"Drug: Cabozantinib",{"label":47,"type":10,"description":48,"interventionNames":49},"Arm VIII (nivolumab, ipilimumab)","Patients with MSI-H or dMMR metastatic colorectal cancer receive nivolumab IV over 30 minutes every 2 or 4 weeks in combination with ipilimumab IV every 3 weeks for up to 4 doses of combination therapy in the absence of disease progression or unacceptable toxicity. Patients may continue to receive single agent nivolumab every 2 or 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,19,14],{"label":51,"type":10,"description":52,"interventionNames":53},"Arm X (nivolumab, fluoropyrimidine, platinum, ipilimumab)","Patients with esophageal squamous cell carcinoma receive nivolumab IV over 30 minutes every 2 or 4 weeks in combination with fluoropyrimidine and platinum-containing chemotherapy for up to 2 years in the absence of disease progression or unacceptable toxicity OR receive nivolumab IV every 2 or 3 weeks in combination with ipilimumab IV every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may then continue receiving fluoropyrimidine and platinum-containing chemotherapy in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,54,19,14,55],"Drug: Fluoropyrimidine","Drug: Platinum Compound",{"label":57,"type":10,"description":58,"interventionNames":59},"Arm XI (nivolumab, fluoropyrimidine, platinum)","Patients with gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receive nivolumab IV over 30 minutes in combination with fluoropyrimidine and platinum-containing chemotherapy every 2 or 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.",[13,54,14,55],[61,71,77,81,97,118,125],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"PROCEDURE","Biospecimen Collection","Undergo collection of blood, CSF, tissue, stool and urine samples",[9,16,21,26,30,34,38,42,47,51,57],[67,68,69,70],"Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection",{"type":72,"name":73,"description":74,"armGroupLabels":75,"otherNames":76},"DRUG","Cabozantinib","Given PO",[42],null,{"type":72,"name":78,"description":79,"armGroupLabels":80,"otherNames":76},"Fluoropyrimidine","Given fluoropyrimidine",[51,57],{"type":82,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"BIOLOGICAL","Ipilimumab","Given IV",[16,26,30,34,38,42,47,51],[87,88,89,90,91,92,93,94,95,96],"Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS 734016","BMS-734016","BMS734016","Ipilimumab Biosimilar CS1002","MDX 010","MDX-010","MDX-CTLA4","MDX010","Yervoy",{"type":82,"name":98,"description":84,"armGroupLabels":99,"otherNames":100},"Nivolumab",[9,16,21,26,30,34,38,42,47,51,57],[101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117],"ABP 206","BCD-263","BMS 936558","BMS-936558","BMS936558","CMAB819","MDX 1106","MDX-1106","MDX1106","NIVO","Nivolumab Biosimilar ABP 206","Nivolumab Biosimilar BCD-263","Nivolumab Biosimilar CMAB819","ONO 4538","ONO-4538","ONO4538","Opdivo",{"type":72,"name":119,"description":120,"armGroupLabels":121,"otherNames":122},"Platinum Compound","Given platinum containing chemotherapy",[51,57],[123,124],"Platinum Agents","Platinum-Based Chemotherapeutic Agent",{"type":72,"name":126,"description":127,"armGroupLabels":128,"otherNames":129},"Platinum Doublet","Given platinum doublet",[21,34],[130,131,132,133,134,135],"Platinum Doublets","Platinum-based Chemotherapy Doublet","Platinum-based Chemotherapy Doublets","Platinum-based Double Chemotherapy Combination","Platinum-based Doublet","Platinum-based Doublets",[137],{"name":138,"affiliation":139,"role":140},"Hussein A Tawbi","University of Texas MD Anderson Cancer Center LAO","PRINCIPAL_INVESTIGATOR",[142,156,166,183,199,208,223,233,243,249,265,278,290,304,318,330,339,349,363,376,387,402,418,432,437,452,462,472,488,500,512,521,533,545,557,566,575,590,606,618,630,641,657,667,681,697,707,719,734,748,758,774],{"facility":143,"status":144,"city":145,"state":146,"zip":147,"country":148,"countryCode":149,"cosmosGeoPoint":150,"geoPoint":155,"contacts":76},"University of Alabama at Birmingham Cancer Center","ACTIVE_NOT_RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":151,"coordinates":152},"Point",[153,154],-86.80249,33.52066,{"lat":154,"lon":153},{"facility":157,"status":144,"city":158,"state":159,"zip":160,"country":148,"countryCode":149,"cosmosGeoPoint":161,"geoPoint":165,"contacts":76},"Stanford Cancer Institute Palo Alto","Palo Alto","California","94304",{"type":151,"coordinates":162},[163,164],-122.14302,37.44188,{"lat":164,"lon":163},{"facility":167,"status":168,"city":169,"state":159,"zip":170,"country":148,"countryCode":149,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"University of California Davis Comprehensive Cancer Center","RECRUITING","Sacramento","95817",{"type":151,"coordinates":172},[173,174],-121.4944,38.58157,{"lat":174,"lon":173},[177,181],{"name":178,"role":179,"phone":180,"phoneExt":76,"email":76},"Site Public Contact","CONTACT","916-734-3089",{"name":182,"role":140,"phone":76,"phoneExt":76,"email":76},"Surbhi Singhal",{"facility":184,"status":168,"city":185,"state":186,"zip":187,"country":148,"countryCode":149,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Smilow Cancer Center\u002FYale-New Haven Hospital","New Haven","Connecticut","06510",{"type":151,"coordinates":189},[190,191],-72.92816,41.30815,{"lat":191,"lon":190},[194,197],{"name":178,"role":179,"phone":195,"phoneExt":76,"email":196},"203-785-5702","canceranswers@yale.edu",{"name":198,"role":140,"phone":76,"phoneExt":76,"email":76},"Patricia M. LoRusso",{"facility":200,"status":168,"city":185,"state":186,"zip":201,"country":148,"countryCode":149,"cosmosGeoPoint":202,"geoPoint":204,"contacts":205},"Yale University","06520",{"type":151,"coordinates":203},[190,191],{"lat":191,"lon":190},[206,207],{"name":178,"role":179,"phone":195,"phoneExt":76,"email":196},{"name":198,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":209,"status":168,"city":210,"state":211,"zip":212,"country":148,"countryCode":149,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"MedStar Georgetown University Hospital","Washington D.C.","District of Columbia","20007",{"type":151,"coordinates":214},[215,216],-77.03637,38.89511,{"lat":216,"lon":215},[219,221],{"name":178,"role":179,"phone":220,"phoneExt":76,"email":76},"202-444-2223",{"name":222,"role":140,"phone":76,"phoneExt":76,"email":76},"Geoffrey T. Gibney",{"facility":224,"status":144,"city":225,"state":226,"zip":227,"country":148,"countryCode":149,"cosmosGeoPoint":228,"geoPoint":232,"contacts":76},"Emory University Hospital\u002FWinship Cancer Institute","Atlanta","Georgia","30322",{"type":151,"coordinates":229},[230,231],-84.38798,33.749,{"lat":231,"lon":230},{"facility":234,"status":144,"city":235,"state":236,"zip":237,"country":148,"countryCode":149,"cosmosGeoPoint":238,"geoPoint":242,"contacts":76},"Northwestern University","Chicago","Illinois","60611",{"type":151,"coordinates":239},[240,241],-87.65005,41.85003,{"lat":241,"lon":240},{"facility":244,"status":144,"city":235,"state":236,"zip":245,"country":148,"countryCode":149,"cosmosGeoPoint":246,"geoPoint":248,"contacts":76},"University of Chicago Comprehensive Cancer Center","60637",{"type":151,"coordinates":247},[240,241],{"lat":241,"lon":240},{"facility":250,"status":168,"city":251,"state":252,"zip":253,"country":148,"countryCode":149,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"University of Kansas Clinical Research Center","Fairway","Kansas","66205",{"type":151,"coordinates":255},[256,257],-94.6319,39.02223,{"lat":257,"lon":256},[260,263],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},"913-588-3671","KUCC_Navigation@kumc.edu",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},"Joaquina C. Baranda",{"facility":266,"status":168,"city":267,"state":252,"zip":268,"country":148,"countryCode":149,"cosmosGeoPoint":269,"geoPoint":273,"contacts":274},"HaysMed","Hays","67601",{"type":151,"coordinates":270},[271,272],-99.32677,38.87918,{"lat":272,"lon":271},[275,277],{"name":178,"role":179,"phone":276,"phoneExt":76,"email":76},"785-623-5774",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":279,"status":168,"city":280,"state":252,"zip":281,"country":148,"countryCode":149,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"University of Kansas Cancer Center","Kansas City","66160",{"type":151,"coordinates":283},[284,285],-94.62746,39.11417,{"lat":285,"lon":284},[288,289],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":291,"status":168,"city":292,"state":252,"zip":293,"country":148,"countryCode":149,"cosmosGeoPoint":294,"geoPoint":298,"contacts":299},"Lawrence Memorial Hospital","Lawrence","66044",{"type":151,"coordinates":295},[296,297],-95.23525,38.97167,{"lat":297,"lon":296},[300,303],{"name":178,"role":179,"phone":301,"phoneExt":76,"email":302},"785-505-2800","Stephanie.Norris@LMH.ORG",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":305,"status":168,"city":306,"state":252,"zip":307,"country":148,"countryCode":149,"cosmosGeoPoint":308,"geoPoint":312,"contacts":313},"The University of Kansas Cancer Center - Olathe","Olathe","66061",{"type":151,"coordinates":309},[310,311],-94.81913,38.8814,{"lat":311,"lon":310},[314,317],{"name":178,"role":179,"phone":315,"phoneExt":76,"email":316},"913-588-1569","OlatheCCResearch@kumc.edu",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":319,"status":168,"city":320,"state":252,"zip":321,"country":148,"countryCode":149,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"University of Kansas Cancer Center-Overland Park","Overland Park","66210",{"type":151,"coordinates":323},[324,325],-94.67079,38.98223,{"lat":325,"lon":324},[328,329],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":331,"status":168,"city":320,"state":252,"zip":332,"country":148,"countryCode":149,"cosmosGeoPoint":333,"geoPoint":335,"contacts":336},"University of Kansas Hospital-Indian Creek Campus","66211",{"type":151,"coordinates":334},[324,325],{"lat":325,"lon":324},[337,338],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":340,"status":341,"city":342,"state":252,"zip":343,"country":148,"countryCode":149,"cosmosGeoPoint":344,"geoPoint":348,"contacts":76},"Mercy Hospital Pittsburg","SUSPENDED","Pittsburg","66762",{"type":151,"coordinates":345},[346,347],-94.70496,37.41088,{"lat":347,"lon":346},{"facility":350,"status":168,"city":351,"state":252,"zip":352,"country":148,"countryCode":149,"cosmosGeoPoint":353,"geoPoint":357,"contacts":358},"Salina Regional Health Center","Salina","67401",{"type":151,"coordinates":354},[355,356],-97.61142,38.84028,{"lat":356,"lon":355},[359,362],{"name":178,"role":179,"phone":360,"phoneExt":76,"email":361},"785-452-7038","mleepers@srhc.com",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":364,"status":168,"city":365,"state":252,"zip":366,"country":148,"countryCode":149,"cosmosGeoPoint":367,"geoPoint":371,"contacts":372},"University of Kansas Health System Saint Francis Campus","Topeka","66606",{"type":151,"coordinates":368},[369,370],-95.67804,39.04833,{"lat":370,"lon":369},[373,375],{"name":178,"role":179,"phone":374,"phoneExt":76,"email":76},"785-295-8000",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":377,"status":168,"city":378,"state":252,"zip":253,"country":148,"countryCode":149,"cosmosGeoPoint":379,"geoPoint":383,"contacts":384},"University of Kansas Hospital-Westwood Cancer Center","Westwood",{"type":151,"coordinates":380},[381,382],-94.6169,39.04056,{"lat":382,"lon":381},[385,386],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":388,"status":168,"city":389,"state":390,"zip":391,"country":148,"countryCode":149,"cosmosGeoPoint":392,"geoPoint":396,"contacts":397},"University of Kentucky\u002FMarkey Cancer Center","Lexington","Kentucky","40536",{"type":151,"coordinates":393},[394,395],-84.47772,37.98869,{"lat":395,"lon":394},[398,400],{"name":178,"role":179,"phone":399,"phoneExt":76,"email":76},"859-257-3379",{"name":401,"role":140,"phone":76,"phoneExt":76,"email":76},"Susanne M. Arnold",{"facility":403,"status":168,"city":404,"state":405,"zip":406,"country":148,"countryCode":149,"cosmosGeoPoint":407,"geoPoint":411,"contacts":412},"Johns Hopkins University\u002FSidney Kimmel Cancer Center","Baltimore","Maryland","21287",{"type":151,"coordinates":408},[409,410],-76.61219,39.29038,{"lat":410,"lon":409},[413,416],{"name":178,"role":179,"phone":414,"phoneExt":76,"email":415},"410-955-8804","jhcccro@jhmi.edu",{"name":417,"role":140,"phone":76,"phoneExt":76,"email":76},"Julie R. Brahmer",{"facility":419,"status":168,"city":420,"state":405,"zip":421,"country":148,"countryCode":149,"cosmosGeoPoint":422,"geoPoint":426,"contacts":427},"National Cancer Institute Developmental Therapeutics Clinic","Bethesda","20892",{"type":151,"coordinates":423},[424,425],-77.10026,38.98067,{"lat":425,"lon":424},[428,430],{"name":178,"role":179,"phone":429,"phoneExt":76,"email":76},"800-411-1222",{"name":431,"role":140,"phone":76,"phoneExt":76,"email":76},"A P. Chen",{"facility":433,"status":144,"city":420,"state":405,"zip":421,"country":148,"countryCode":149,"cosmosGeoPoint":434,"geoPoint":436,"contacts":76},"National Institutes of Health Clinical Center",{"type":151,"coordinates":435},[424,425],{"lat":425,"lon":424},{"facility":438,"status":168,"city":439,"state":440,"zip":441,"country":148,"countryCode":149,"cosmosGeoPoint":442,"geoPoint":446,"contacts":447},"Massachusetts General Hospital Cancer Center","Boston","Massachusetts","02114",{"type":151,"coordinates":443},[444,445],-71.05977,42.35843,{"lat":445,"lon":444},[448,450],{"name":178,"role":179,"phone":449,"phoneExt":76,"email":76},"877-726-5130",{"name":451,"role":140,"phone":76,"phoneExt":76,"email":76},"Patrick A. Ott",{"facility":453,"status":168,"city":439,"state":440,"zip":454,"country":148,"countryCode":149,"cosmosGeoPoint":455,"geoPoint":457,"contacts":458},"Dana-Farber Cancer Institute","02215",{"type":151,"coordinates":456},[444,445],{"lat":445,"lon":444},[459,461],{"name":178,"role":179,"phone":460,"phoneExt":76,"email":76},"877-442-3324",{"name":451,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":463,"status":144,"city":464,"state":465,"zip":466,"country":148,"countryCode":149,"cosmosGeoPoint":467,"geoPoint":471,"contacts":76},"Wayne State University\u002FKarmanos Cancer Institute","Detroit","Michigan","48201",{"type":151,"coordinates":468},[469,470],-83.04575,42.33143,{"lat":470,"lon":469},{"facility":473,"status":168,"city":474,"state":475,"zip":476,"country":148,"countryCode":149,"cosmosGeoPoint":477,"geoPoint":481,"contacts":482},"Siteman Cancer Center at Saint Peters Hospital","City of Saint Peters","Missouri","63376",{"type":151,"coordinates":478},[479,480],-90.62651,38.80033,{"lat":480,"lon":479},[483,486],{"name":178,"role":179,"phone":484,"phoneExt":76,"email":485},"800-600-3606","info@siteman.wustl.edu",{"name":487,"role":140,"phone":76,"phoneExt":76,"email":76},"Tanner M. Johanns",{"facility":489,"status":168,"city":490,"state":475,"zip":491,"country":148,"countryCode":149,"cosmosGeoPoint":492,"geoPoint":496,"contacts":497},"Siteman Cancer Center at West County Hospital","Creve Coeur","63141",{"type":151,"coordinates":493},[494,495],-90.42262,38.66089,{"lat":495,"lon":494},[498,499],{"name":178,"role":179,"phone":484,"phoneExt":76,"email":485},{"name":487,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":501,"status":168,"city":280,"state":475,"zip":502,"country":148,"countryCode":149,"cosmosGeoPoint":503,"geoPoint":507,"contacts":508},"University Health Truman Medical Center","64108",{"type":151,"coordinates":504},[505,506],-94.57857,39.09973,{"lat":506,"lon":505},[509,511],{"name":178,"role":179,"phone":510,"phoneExt":76,"email":76},"816-404-4375",{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":513,"status":168,"city":280,"state":475,"zip":514,"country":148,"countryCode":149,"cosmosGeoPoint":515,"geoPoint":517,"contacts":518},"University of Kansas Cancer Center - North","64154",{"type":151,"coordinates":516},[505,506],{"lat":506,"lon":505},[519,520],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":522,"status":168,"city":523,"state":475,"zip":524,"country":148,"countryCode":149,"cosmosGeoPoint":525,"geoPoint":529,"contacts":530},"University of Kansas Cancer Center - Lee's Summit","Lee's Summit","64064",{"type":151,"coordinates":526},[527,528],-94.38217,38.91084,{"lat":528,"lon":527},[531,532],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":534,"status":168,"city":535,"state":475,"zip":536,"country":148,"countryCode":149,"cosmosGeoPoint":537,"geoPoint":541,"contacts":542},"University of Kansas Cancer Center at North Kansas City Hospital","North Kansas City","64116",{"type":151,"coordinates":538},[539,540],-94.56218,39.13,{"lat":540,"lon":539},[543,544],{"name":178,"role":179,"phone":261,"phoneExt":76,"email":262},{"name":264,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":546,"status":168,"city":547,"state":475,"zip":548,"country":148,"countryCode":149,"cosmosGeoPoint":549,"geoPoint":553,"contacts":554},"Washington University School of Medicine","St Louis","63110",{"type":151,"coordinates":550},[551,552],-90.19789,38.62727,{"lat":552,"lon":551},[555,556],{"name":178,"role":179,"phone":484,"phoneExt":76,"email":485},{"name":487,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":558,"status":168,"city":547,"state":475,"zip":559,"country":148,"countryCode":149,"cosmosGeoPoint":560,"geoPoint":562,"contacts":563},"Siteman Cancer Center-South County","63129",{"type":151,"coordinates":561},[551,552],{"lat":552,"lon":551},[564,565],{"name":178,"role":179,"phone":484,"phoneExt":76,"email":485},{"name":487,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":567,"status":168,"city":547,"state":475,"zip":568,"country":148,"countryCode":149,"cosmosGeoPoint":569,"geoPoint":571,"contacts":572},"Siteman Cancer Center at Christian Hospital","63136",{"type":151,"coordinates":570},[551,552],{"lat":552,"lon":551},[573,574],{"name":178,"role":179,"phone":484,"phoneExt":76,"email":485},{"name":487,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":576,"status":168,"city":577,"state":578,"zip":579,"country":148,"countryCode":149,"cosmosGeoPoint":580,"geoPoint":584,"contacts":585},"Rutgers Cancer Institute of New Jersey","New Brunswick","New Jersey","08903",{"type":151,"coordinates":581},[582,583],-74.45182,40.48622,{"lat":583,"lon":582},[586,588],{"name":178,"role":179,"phone":587,"phoneExt":76,"email":76},"732-235-7356",{"name":589,"role":140,"phone":76,"phoneExt":76,"email":76},"Sarah A. Weiss",{"facility":591,"status":168,"city":592,"state":593,"zip":594,"country":148,"countryCode":149,"cosmosGeoPoint":595,"geoPoint":599,"contacts":600},"NYU Langone Hospital - Long Island","Mineola","New York","11501",{"type":151,"coordinates":596},[597,598],-73.64068,40.74927,{"lat":598,"lon":597},[601,604],{"name":178,"role":179,"phone":602,"phoneExt":76,"email":603},"212-263-4432","cancertrials@nyulangone.org",{"name":605,"role":140,"phone":76,"phoneExt":76,"email":76},"Janice M. Mehnert",{"facility":607,"status":168,"city":593,"state":593,"zip":608,"country":148,"countryCode":149,"cosmosGeoPoint":609,"geoPoint":613,"contacts":614},"Laura and Isaac Perlmutter Cancer Center at NYU Langone","10016",{"type":151,"coordinates":610},[611,612],-74.00597,40.71427,{"lat":612,"lon":611},[615,617],{"name":178,"role":179,"phone":76,"phoneExt":76,"email":616},"CancerTrials@nyulangone.org",{"name":605,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":619,"status":168,"city":593,"state":593,"zip":620,"country":148,"countryCode":149,"cosmosGeoPoint":621,"geoPoint":623,"contacts":624},"NYP\u002FColumbia University Medical Center\u002FHerbert Irving Comprehensive Cancer Center","10032",{"type":151,"coordinates":622},[611,612],{"lat":612,"lon":611},[625,628],{"name":178,"role":179,"phone":626,"phoneExt":76,"email":627},"212-342-5162","cancerclinicaltrials@cumc.columbia.edu",{"name":629,"role":140,"phone":76,"phoneExt":76,"email":76},"Brian S. Henick",{"facility":631,"status":168,"city":593,"state":593,"zip":632,"country":148,"countryCode":149,"cosmosGeoPoint":633,"geoPoint":635,"contacts":636},"NYP\u002FWeill Cornell Medical Center","10065",{"type":151,"coordinates":634},[611,612],{"lat":612,"lon":611},[637,639],{"name":178,"role":179,"phone":638,"phoneExt":76,"email":76},"212-746-1848",{"name":640,"role":140,"phone":76,"phoneExt":76,"email":76},"Ashish Saxena",{"facility":642,"status":168,"city":643,"state":644,"zip":645,"country":148,"countryCode":149,"cosmosGeoPoint":646,"geoPoint":650,"contacts":651},"Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":151,"coordinates":647},[648,649],-82.99879,39.96118,{"lat":649,"lon":648},[652,655],{"name":178,"role":179,"phone":653,"phoneExt":76,"email":654},"800-293-5066","Jamesline@osumc.edu",{"name":656,"role":140,"phone":76,"phoneExt":76,"email":76},"Yuanquan Yang",{"facility":658,"status":144,"city":659,"state":660,"zip":661,"country":148,"countryCode":149,"cosmosGeoPoint":662,"geoPoint":666,"contacts":76},"Thomas Jefferson University Hospital","Philadelphia","Pennsylvania","19107",{"type":151,"coordinates":663},[664,665],-75.16362,39.95238,{"lat":665,"lon":664},{"facility":668,"status":168,"city":669,"state":660,"zip":670,"country":148,"countryCode":149,"cosmosGeoPoint":671,"geoPoint":675,"contacts":676},"University of Pittsburgh Cancer Institute (UPCI)","Pittsburgh","15232",{"type":151,"coordinates":672},[673,674],-79.99589,40.44062,{"lat":674,"lon":673},[677,679],{"name":178,"role":179,"phone":678,"phoneExt":76,"email":76},"412-647-8073",{"name":680,"role":140,"phone":76,"phoneExt":76,"email":76},"Yana Najjar",{"facility":682,"status":168,"city":683,"state":684,"zip":685,"country":148,"countryCode":149,"cosmosGeoPoint":686,"geoPoint":690,"contacts":691},"UT Southwestern Simmons Cancer Center - RedBird","Dallas","Texas","75237",{"type":151,"coordinates":687},[688,689],-96.80667,32.78306,{"lat":689,"lon":688},[692,695],{"name":178,"role":179,"phone":693,"phoneExt":76,"email":694},"214-648-7097","canceranswerline@utsouthwestern.edu",{"name":696,"role":140,"phone":76,"phoneExt":76,"email":76},"Hans Hammers",{"facility":698,"status":168,"city":683,"state":684,"zip":699,"country":148,"countryCode":149,"cosmosGeoPoint":700,"geoPoint":702,"contacts":703},"UT Southwestern\u002FSimmons Cancer Center-Dallas","75390",{"type":151,"coordinates":701},[688,689],{"lat":689,"lon":688},[704,706],{"name":178,"role":179,"phone":693,"phoneExt":76,"email":705},"canceranswerline@UTSouthwestern.edu",{"name":696,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":708,"status":168,"city":709,"state":684,"zip":710,"country":148,"countryCode":149,"cosmosGeoPoint":711,"geoPoint":715,"contacts":716},"UT Southwestern\u002FSimmons Cancer Center-Fort Worth","Fort Worth","76104",{"type":151,"coordinates":712},[713,714],-97.32085,32.72541,{"lat":714,"lon":713},[717,718],{"name":178,"role":179,"phone":693,"phoneExt":76,"email":705},{"name":696,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":720,"status":168,"city":721,"state":684,"zip":722,"country":148,"countryCode":149,"cosmosGeoPoint":723,"geoPoint":727,"contacts":728},"UT MD Anderson Cancer Center","Houston","77030",{"type":151,"coordinates":724},[725,726],-95.36327,29.76328,{"lat":726,"lon":725},[729,732],{"name":178,"role":179,"phone":730,"phoneExt":76,"email":731},"866-632-6789","askmdanderson@mdanderson.org",{"name":733,"role":140,"phone":76,"phoneExt":76,"email":76},"Ecaterina E. Ileana Dumbrava",{"facility":735,"status":168,"city":736,"state":684,"zip":737,"country":148,"countryCode":149,"cosmosGeoPoint":738,"geoPoint":742,"contacts":743},"UT Southwestern Clinical Center at Richardson\u002FPlano","Richardson","75080",{"type":151,"coordinates":739},[740,741],-96.72972,32.94818,{"lat":741,"lon":740},[744,747],{"name":178,"role":179,"phone":745,"phoneExt":76,"email":746},"972-669-7044","Suzanne.cole@utsouthwestern.edu",{"name":696,"role":140,"phone":76,"phoneExt":76,"email":76},{"facility":749,"status":144,"city":750,"state":751,"zip":752,"country":148,"countryCode":149,"cosmosGeoPoint":753,"geoPoint":757,"contacts":76},"Huntsman Cancer Institute\u002FUniversity of Utah","Salt Lake City","Utah","84112",{"type":151,"coordinates":754},[755,756],-111.89105,40.76078,{"lat":756,"lon":755},{"facility":759,"status":168,"city":760,"state":761,"zip":762,"country":148,"countryCode":149,"cosmosGeoPoint":763,"geoPoint":767,"contacts":768},"VCU Massey Comprehensive Cancer Center","Richmond","Virginia","23298",{"type":151,"coordinates":764},[765,766],-77.46026,37.55376,{"lat":766,"lon":765},[769,772],{"name":178,"role":179,"phone":770,"phoneExt":76,"email":771},"804-628-6430","CTOclinops@vcu.edu",{"name":773,"role":140,"phone":76,"phoneExt":76,"email":76},"Andrew Poklepovic",{"facility":775,"status":341,"city":776,"state":777,"zip":778,"country":779,"countryCode":780,"cosmosGeoPoint":781,"geoPoint":785,"contacts":76},"University Health Network-Princess Margaret Hospital","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":151,"coordinates":782},[783,784],-79.39864,43.70643,{"lat":784,"lon":783},{"type":787,"investigatorFullName":76,"investigatorTitle":76,"investigatorAffiliation":76,"oldNameTitle":76,"oldOrganization":76},"SPONSOR","100348403","phase-1-testing-an-immunotherapy-anti-cancer-drug-nivolumab-for-advanced-cancers-in-patients-with-autoimmune-disorders-aim-nivo-100348403",false,"NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","Inclusion Criteria:\n\n* Patients can have either histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or have a malignancy for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting, as well as the neoadjuvant or perioperative setting in which such treatment is considered standard of care or has been approved. Eligible tumor types include solid tumors and malignancies in which there is known evidence of clinical activity for single agent PD-1 or PD-L1 antibodies. Nivolumab or other PD1\u002FPD-L1 inhibitors are FDA-approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), Merkel cell cancer, bladder cancer, renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), cervical cancer, head and neck cancer, Hodgkin lymphoma (HL), metastatic small cell lung cancer (SCLC), and any solid tumor with microsatellite instability (MSI)-high status confirmed. Patients with HL are eligible but must follow standard response criteria. Additional tumor types may be eligible on a case by case basis upon discussion with principal investigator (PI)\n\n  * Patients enrolling on the trial for adjuvant use will be restricted to those with histology for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting including but not limited to NSCLC, melanoma, RCC, cervical cancer, and bladder cancer\n  * Patients enrolled on the study can receive Nivolumab with other FDA-approved combinations according to the FDA package insert, including, but not limited to ipilimumab, cabozantinib or chemotherapy\n* Patients who have previously received other forms of immunotherapy (high-dose \\[HD\\] IL-2, IFN, CTLA-4) are allowed. Patients must not have received cytokine immunotherapy for at least 4 weeks before nivolumab administration. Patients who have received prior anti-CTLA4 will be allowed and the washout period is 6 weeks\n* Age \\>= 18 years; children are excluded from this study but may be eligible for future pediatric phase 1 combination trials\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Karnofsky \\>= 60)\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 1,000\u002FmcL\n* Absolute neutrophil count \\>= 500\u002FmcL\n* Platelets \\>= 50,000\u002FmcL\n* Total bilirubin =\\\u003C 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 5 x institutional ULN or =\\\u003C 8 x institutional ULN for patients with liver metastases or an autoimmune disease that is contributing to the elevation of these values\n* Creatinine ULN OR glomerular filtration rate (GFR) \\>= 30 mL\u002Fmin (if using the Cockcroft-Gault formula)\n* Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\n* If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required for at least 4 weeks (or scheduled assessment after the first cycle of treatment), and a risk-benefit analysis (discussion) by the patient and the investigator favors participation in the clinical trial\n* The effects of nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product\n\n  * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy), tubal ligation, or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n  * These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days, and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately. Patients can resume treatment upon termination of a pregnancy or the completion of a successful pregnancy\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with more than one autoimmune disease are eligible. The treating physician would determine which autoimmune disease is dominant and the patient would be treated under that specific cohort (Please note: Patients with more than one autoimmune disease should receive assessments for all previously diagnosed autoimmune diseases. For example, a patient with psoriasis and IBD might be enrolled in the IBD cohort. Disease assessments for both psoriasis and IBD should be obtained, as per protocol. Case report forms \\[CRFs\\] for all relevant autoimmune diseases should be utilized. However, all additional cohort requirements will be considered optional and only the assessments from the assigned cohort will be considered mandatory)\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients with known SSc or DM according to updated classification criteria (Van den Hoogan et al., Arthritis Rheum 2013;65(11):2737-47; Lundberg et al., A\\&R in press). Overlap features are permitted, but patients must meet criteria for a \"primary diagnosis\" of DM or SSc\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for DM or SSc unless specifically excluded\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients must have a baseline computed tomography (CT) of the chest (within 6 months of study entry)\n* RA-SPECIFIC INCLUSION: Rheumatologist-diagnosed RA requiring prior treatment with disease-modifying antirheumatic drugs (DMARDs) before patient was diagnosed with current malignancy. We recommend, but do not require, documentation for meeting 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria for RA\n* RA-SPECIFIC INCLUSION: Prednisone up to 10 mg\u002Fday will be allowed. Intraarticular steroids will be allowed for the treatment of new symptomatic joints\n* RA-SPECIFIC INCLUSION: Nonsteroidal anti-inflammatory drugs (NSAIDs) will be allowed\n* SLE-SPECIFIC INCLUSION: SLE diagnosed by a rheumatologist. The patient should meet the revised 1997 American College of Rheumatology (ACR) classification criteria for SLE, but this is not mandatory\n* ULCERATIVE COLITIS (UC)-SPECIFIC INCLUSION: Diagnosis of UC must be made by endoscopy with biopsies\n* UC-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* UC-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (antigen \\[Ag\\] negative, antibody \\[core (c)Ab\\] negative, antibody \\[surface (s)Ab\\] positive or negative) and Mycobacterium tuberculosis (purified-protein- derivative \\[PPD\\] or enzyme-linked immunospot assay \\[ELISpot or T-spot\\]) or be on appropriate anti-microbial treatment for these infections\n* UC-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission, defined as a Mayo Clinic score (MCS) of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 either without medications, or treated with 5-ASA derivative, probiotic, or prior fecal transplant\n* UC-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on 6-mercaptopurine, azathioprine, methotrexate, or rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* UC-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either be A) in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on a biologic therapy targeting tumor necrosis alpha (TNF-α) (infliximab, adalimumab, golimumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease defined as a MCS of 3-5 and no subscore higher than 2, and an endoscopic subscore of \\\u003C 2 on one of the medications or combination of medications defined for the Moderate or Mild cohort\n* CROHN'S DISEASE (CD)-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* CD-SPECIFIC INCLUSION: If patients have prior known disease in the stomach or small intestines, appropriate endoscopic evaluation (esophagogastroduodenoscopy\u002Fvideo capsule endoscopy) and\u002For imaging (computed tomography or magnetic resonance enterography) must also be current within 4 weeks prior to nivolumab administration\n* CD-SPECIFIC INCLUSION: Deep enteroscopy techniques, such as double balloon enteroscopy, will not be required\n* CD-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (sAg negative, cAb negative, sAb positive or negative) and M. tuberculosis (PPD or ELISpot or T-spot) or be on appropriate anti-microbial treatment for these infections\n* CD-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission as defined by a Crohn's Disease Activity Index (CDAI) \\\u003C 150 either without treatment or on a 5-ASA derivative, probiotic, antibiotics, or following fecal transplant\n* CD-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission as defined by a CDAI \\\u003C 150 on 6-mercaptopurine, azathioprine, methotrexate, rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* CD-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either A) be in clinical remission as defined by a CDAI \\\u003C 150 on biologic therapy targeting TNF-α (infliximab, adalimumab, certolizumab pegol), IL-12\u002F23p40 (ustekinumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease as defined by a CDAI of 150 to 220 on one of medications or combination of medications defined for the Moderate or Mild cohort\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For other autoimmune diseases that cannot be classified, the eligibility criteria will be determined by the managing rheumatologist or other autoimmune disease specialist, based on the clinical judgement and current American College of Radiology (ACR) classification guidelines or other relevant guidelines, as per the disease category in question\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For giant cell arteritis (GCA), patients must have had positive temporal artery biopsy for GCA and abnormal erythrocyte sedimentation rate (ESR) at time of diagnosis\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For polymyalgia rheumatica (PMR), patients must have clinical diagnosis in addition to elevated inflammatory markers including (ESR, C reactive protein \\[CRP\\])\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: Patients can be in remission (with no glucocorticoids or immunosuppressive medications) or have low-moderate activity, which is defined as being on prednisone ≤ 10 mg or equivalent\n* MS-SPECIFIC INCLUSION: Patients must meet 2017 McDonald criteria for the diagnosis of MS (Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 17(2):162-173.)\n* MS-SPECIFIC INCLUSION: Patients with MS can be in remission and can have a history of being on immunomodulatory agents, but at the time of entry into the clinical trial, patients should be off any concurrent MS therapy for at least 2 weeks. Patients receiving concomitant interferon gamma (IFN-γ treatment) will be permitted in the study\n* SJS-SPECIFIC INCLUSION: SjS diagnosed by a rheumatologist or oral medicine provider. The patient should meet the American-European Consensus Criteria for Sjögren's Syndrome (Vitali, et al., 2002). If on treatment, the patient may only be on hydroxychloroquine and prednisone ≤ 10 mg or equivalent\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients with known PsO as diagnosed by a dermatologist or PsA by a rheumatologist and\u002For by Classification for Psoriatic Arthritis (CASPAR) criteria (Tillett et al., 2012)\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients must have stable disease as determined by the investigator with no change in systemic therapy and\u002For biologic therapy for at least 3 months, except for those on tumor necrosis factor (TNF) inhibitors. In the case of TNF inhibition, patients may have transitioned to an alternative biologic therapy with stable disease for at least 4 weeks. For PsA, no change in corticosteroid therapy for at least 1 month prior to baseline and dose must be 10 mg or less\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for PsO or PsA unless specifically excluded\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier have not resolved or stabilized. Palliative (limited-field) radiation therapy (RT) is permitted (2 week washout from start of treatment), if all of the following criteria are met:\n\n  * Repeat imaging demonstrates no new sites of bone metastases\n  * The lesion being considered for palliative radiation is not a target lesion\n* Patients with prior therapy with an anti-PD-1 or anti-PD-L1\n* Patients with prior allogeneic hematologic transplant\n* Patients who are receiving any other anticancer investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* UC-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* UC-SPECIFIC EXCLUSION: Prior colectomy\n* UC-SPECIFIC EXCLUSION: Concurrent primary sclerosing cholangitis (PSC). Patients with PSC can be enrolled on the Other Autoimmune Diseases Cohorts\n* UC-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* CD-SPECIFIC EXCLUSION: Known untreated abscesses, untreated and symptomatic strictures, short gut physiology, or isolated jejunal disease\n* CD-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* CD-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* MS-SPECIFIC EXCLUSION: Patients with MS cannot have medical contraindications to gadolinium-enhanced magnetic resonance imaging (MRI)","ALL","18 Years",{"count":798,"type":799},300,"ESTIMATED","INTERVENTIONAL",[802],"PHASE1","This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and\u002For effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.",[805,806,807,808,809,810,811,812,813,814,815,816,817,818],"Autoimmune Disease","Crohn Disease","Dermatomyositis","Hematopoietic and Lymphoid Cell Neoplasm","Inflammatory Bowel Disease","Malignant Solid Neoplasm","Multiple Sclerosis","Psoriasis","Psoriatic Arthritis","Rheumatoid Arthritis","Sjogren Syndrome","Systemic Lupus Erythematosus","Systemic Scleroderma","Ulcerative Colitis","2026-06-16",{"date":821,"type":822},"2026-06-17","ACTUAL",{"date":824,"type":822},"2019-07-16",{"date":826,"type":799},"2028-03-30",{"name":5,"class":6},52]